Hormonal
Long-term administration of the GLP-1 receptor agonist exendin-4 (Ex4) promotes pancreatic beta-cell growth and survival, but this specific trophic effect is strictly dependent on Insulin Receptor Substrate 2 (Irs2) signaling; without Irs2, Ex4 cannot prevent beta-cell loss or diabetes progression.
This research clarifies that while GLP-1 drugs (like exendin-4/exenatide) effectively stimulate insulin release in the short term regardless of Irs2 status, their ability to actually grow or save beta cells long-term relies on a functional Irs2 signaling pathway. For patients with compromised Irs2 signaling, these drugs may improve blood sugar control via remaining beta cells but may not halt beta-cell loss or regenerate mass.
We conclude that some short term therapeutic effects of glucagon-like peptide 1 receptor agonists can be independent of Irs2, but its long term effects upon beta cell growth and survival are mediated by the Irs2 branch of the insulin/insulin-like growth factor signaling cascade.
Why this rating
High-quality mechanistic evidence using both in vitro (human islets, Min6 cells) and in vivo (WT vs. Irs2-/- mice) models with clear genetic disruption of the target pathway.
Source
Exendin-4 Uses Irs2 Signaling to Mediate Pancreatic β Cell Growth and Function
Sunmin Park et al. · Journal of Biological Chemistry · 2005
DOI 10.1074/jbc.m508307200
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →